CY1110313T1 - Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του - Google Patents

Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του

Info

Publication number
CY1110313T1
CY1110313T1 CY20091100364T CY091100364T CY1110313T1 CY 1110313 T1 CY1110313 T1 CY 1110313T1 CY 20091100364 T CY20091100364 T CY 20091100364T CY 091100364 T CY091100364 T CY 091100364T CY 1110313 T1 CY1110313 T1 CY 1110313T1
Authority
CY
Cyprus
Prior art keywords
factor
polypeptide
amino acid
extracellular matrix
sequence according
Prior art date
Application number
CY20091100364T
Other languages
English (en)
Inventor
Anke Klippel-Giese
Jörg Kaufmann
Rolf Schwarzer
Original Assignee
Silence Therapeutics Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Aktiengesellschaft filed Critical Silence Therapeutics Aktiengesellschaft
Publication of CY1110313T1 publication Critical patent/CY1110313T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα νουκλεϊκό οξύ που κωδικοποιεί ένα παράγοντα που εμπλέκεται σε μια βιολογική διεργασία, όπου η διεργασία είναι μία ρυθμιζόμενη από το μονοπάτι της ΡΙ 3-κινάσης διεργασία, κατά προτίμηση μία διεργασία που επιλέγεται από την ομάδα που περιέχει το μεταβολισμό της γλυκόζης, τις διεργασίες αποστέρησης αμινοξέων και γλυκόζης, το διαβήτη, την επούλωση πληγών, την απόκρισης στο στρες, την απόπτωση, τη μετάσταση, την ογκογένεση, τη κυτταρική μετανάστευση, τη κυτταρική κινητικότητα στο εξωκυττάριο υπόστρωμα και τη κυτταρική ανάπτυξη στο εξωκυττάριο υπόστρωμα, και (όπου) ο παράγοντας είναι ένα πολυπεπτίδιο που περιέχει μια αμινοξική αλληλουχία σύμφωνα με την ΑΛΛΗΛΟΥΧΙΑ ΜΕ ΑΡΙΘΜΟ ΑΝΑΓΝΩΡΙΣΗΣ 1, ή ένα πολυπεπτίδιο που έχει μια αλληλουχία σύμφωνα με τις καταχωρήσεις στις τράπεζες δεδομένων gi 9506687 ή ΝΡ_061931, κατά προτίμηση ΝΡ_061931.1.
CY20091100364T 2002-10-18 2009-03-26 Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του CY1110313T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023384 2002-10-18
EP03769423A EP1551868B1 (en) 2002-10-18 2003-10-20 Factor involved in metastasis and uses thereof

Publications (1)

Publication Number Publication Date
CY1110313T1 true CY1110313T1 (el) 2015-01-14

Family

ID=32103889

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100364T CY1110313T1 (el) 2002-10-18 2009-03-26 Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του

Country Status (19)

Country Link
US (2) US20060240022A1 (el)
EP (2) EP1551868B1 (el)
JP (2) JP4820092B2 (el)
KR (1) KR101154130B1 (el)
CN (1) CN100564524C (el)
AT (1) ATE420102T1 (el)
AU (2) AU2003278112A1 (el)
BR (1) BR0315411A (el)
CA (1) CA2501333A1 (el)
CY (1) CY1110313T1 (el)
DE (1) DE60325754D1 (el)
DK (1) DK1551868T3 (el)
ES (1) ES2319891T3 (el)
IL (1) IL167801A (el)
MX (1) MXPA05004134A (el)
PT (1) PT1551868E (el)
SI (1) SI1551868T1 (el)
WO (1) WO2004035615A2 (el)
ZA (1) ZA200502483B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
CA2501333A1 (en) * 2002-10-18 2004-04-29 Atugen Ag Factor involved in metastasis and uses thereof
CN101123994B (zh) 2004-08-16 2012-11-14 夸克医药公司 Rtp801的抑制剂的治疗性用途
CN100357323C (zh) * 2006-01-05 2007-12-26 清华大学 一种细胞迁移相关蛋白及其编码基因与应用
DOP2007000015A (es) * 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
DK2895607T3 (da) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
ATE228529T1 (de) 1996-08-30 2002-12-15 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1071753A2 (en) 1998-04-20 2001-01-31 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1185543A4 (en) * 1999-06-11 2003-09-03 Human Genome Sciences Inc 50 HUMAN-SECRETED PROTEINS
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
AU2002220920A1 (en) * 2000-12-08 2002-06-18 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
EP2311978A1 (en) * 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
CA2501333A1 (en) * 2002-10-18 2004-04-29 Atugen Ag Factor involved in metastasis and uses thereof
CN101123994B (zh) * 2004-08-16 2012-11-14 夸克医药公司 Rtp801的抑制剂的治疗性用途

Also Published As

Publication number Publication date
ES2319891T3 (es) 2009-05-14
WO2004035615A3 (en) 2004-06-03
BR0315411A (pt) 2005-08-16
DE60325754D1 (de) 2009-02-26
ZA200502483B (en) 2005-11-30
AU2003278112A1 (en) 2004-05-04
DK1551868T3 (da) 2009-04-20
EP1551868B1 (en) 2009-01-07
PT1551868E (pt) 2009-04-06
US20100285038A1 (en) 2010-11-11
MXPA05004134A (es) 2005-10-05
ATE420102T1 (de) 2009-01-15
CN1705746A (zh) 2005-12-07
IL167801A (en) 2012-10-31
JP2011125339A (ja) 2011-06-30
WO2004035615A2 (en) 2004-04-29
US20060240022A1 (en) 2006-10-26
JP2006520183A (ja) 2006-09-07
EP2072619A1 (en) 2009-06-24
KR20050056244A (ko) 2005-06-14
KR101154130B1 (ko) 2012-06-12
EP1551868A2 (en) 2005-07-13
JP4820092B2 (ja) 2011-11-24
CN100564524C (zh) 2009-12-02
CA2501333A1 (en) 2004-04-29
AU2010246370A1 (en) 2010-12-16
SI1551868T1 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
CY1110313T1 (el) Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Sakamoto et al. Neck length and processivity of myosin V
Joester et al. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Doliana et al. EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
Nordström et al. The amphioxus (Branchiostoma floridae) genome contains a highly diversified set of G protein-coupled receptors
ATE514781T1 (de) Nukleinsäuresequenzen, die für proteine in zusammenhang mit abiotischer stressreaktion kodieren, sowie pflanzenzellen und pflanzen mit erhöhter umweltstressverträglichkeit
ATE79721T1 (de) Bacillus thuringiensis-stamm.
FR2631974B1 (fr) Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
BR9610357B1 (pt) composição sinterizada artificial bioativa, estrutura microporosa cerámica aparente, dispositivo implantável, processo para o cultivo de células de ossos funcionais e kit para monitorar e quantificar a atividade das referidas células
ATE346945T1 (de) Stress-gekoppeltes signaltransduktionprotein und dessen verwendung in pflanzen
ATE178356T1 (de) Neues koleopterenaktives isolat von bacillus thuringiensis und neues gen, dass für ein koleopteren-aktives toxin kodiert
TR199802252T2 (xx) N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
DE69839768D1 (de) Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
ES2089044T3 (es) Fragmento de dna que codifica un polipeptido que presenta actividad nitrilo hidratasa, un transformante que contiene el fragmento de dna y un proceso para la produccion de amidas utilizando el transformante.
SE8801701D0 (sv) Production technology based on enzymic method
DE60328708D1 (de) Sol-gel-biosensoren
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DK2186530T3 (da) Promotere, der udviser endothelcellespecificitet og fremgangsmåder til anvendelse heraf
Fernández et al. Molecular determinants of negative regulation of the Bradyrhizobium diazoefficiens transcription factor FixK 2
ATE61631T1 (de) Gen fuer ein protein mit insektizider wirkung.
DE60221550D1 (de) Methode zur bestimmung der zellzyklusposition
DK1164190T3 (da) Rheumatoid arthrit-gen og fremgangsmåde til diagnose af rheumatoid arthrit